Transaction · 0002001011-25-000010

Reardon Andrew

Reardon Andrew, CLO, SECY, reported a transaction classified as grant at LIGAND PHARMACEUTICALS INC involving 6928.000000 shares for an estimated $0.00. Reported holdings after the transaction were 29462.000000 shares. A 10b5-1 reference was not detected in the stored filing text.

grantSEC transaction code ACLO, SECY
LGNDLIGAND PHARMACEUTICALS INC
Filing timeFeb 20
Trade dateFeb 14, 2025
Filing · SECView on SEC
InsiderProfile

Price performance since filing

Close on the filing date, the pre-filing context, and the forward return at standard windows
Price at filing
…
Pre-filing
…
Returns since
…

LGND price since this filing

30 days of pre-filing context and vertical markers at the filing date plus 7d / 30d / 90d / 180d / 1y afterwards
LGND since 2025-02-20Filed 566 days ago · 30 days of pre-filing context shaded
Loading…
Filing datePost-filing windows (7d, 30d, 90d, 180d, 1y)30 days of pre-filing context

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
grant
Code A
Identifier
0002001011-25-000010
Common Stock
Transaction date
Feb 14, 2025
Filed Feb 20, 2025, 01:37 AM · 6d delay
Shares
6.92k sh
$0 per share
Estimated value
$0
Computed from shares × price
Holdings after
29.4k sh
Direct

Filing warnings

Notes recorded with this filing
1 warning
delayed filingThe filing was reported 6 calendar days after the transaction date.

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $10.0MLarge $100M
Delayed Filing Direct Ownership
-22score
Filing-only score

-22

Compact filing score computed from stored Form 4 facts. Version v1.

Low filing signal

This filing has a meaningfully negative filing-only score. It is likely less useful as a positive insider-activity signal.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

CLO & Secretary

Officer YesDirector No10% NoOther No
Footnotes & amended
  1. F1

    Represents shares of common stock issued upon the vesting and certification of performance stock units (PSUs).

  2. F2

    Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of performance stock units.

  3. F3

    Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of restricted stock units.

Original filing · 0002001011-25-000010
Related transactions

0 other filings

Same reporting owner
Recent company activity

0 recent txs

LGND